Extended hepatitis C treatment after liver transplant may benefit patients

May 02, 2010

Extending hepatitis C treatment for liver transplant patients beyond current standards results in high clearance rates of the hepatitis C virus from the blood, and a low relapse rate, according to a study by Henry Ford Hospital.

"We found that patients who achieved a sustained virological response were more likely to have had extended treatment after transplant," says Matthew Moeller, M.D., gastroenterology fellow at Henry Ford Hospital and lead author of the study.

"In the study, we saw a trend toward decreased mortality as sustained virological response was found to be associated with a 100 percent five-year survival rate vs. 86 percent for those without."

Although, statistically insignificant, the trend could show significance with longer follow-up and a larger sample size, explains Dr. Moeller.

Study results will be presented May 2 at the Digestive Diseases Week conference in New Orleans.

The study looked at 241 consecutive patients from 1999-2006. Patients were offered treatment if they tested positive for , had recurrent hepatitis C with at least Stage I fibrosis on biopsy, and stable for a minimum of three months. Patients received either non-pegylated interferon tiw or pegylated interferon weekly in combination with ribavirin.

Of the study patients with hepatitis C, 66 were eligible for treatment, and 22 achieved sustained virological response. Only two patients (8 percent) relapsed. This is in contrast to typical relapse rates of 30-35 percent in non-transplant patients treated with standard therapy. Genotype 1 patients failed more than genotype 2 or 3 patients in achieving sustained virological response (27 percent vs. 70 percent).

Dr. Moeller notes that 35 percent of patients who went on to achieve sustained virological response first became virus-negative at or following week 24.

"Our results suggest that even if patients are positive at week 24, there is still a 35 percent chance that they can achieve sustained viral clearance with extended treatment," says Dr. Moeller.

Explore further: Ebola mistakes should serve a lesson says WHO

add to favorites email to friend print save as pdf

Related Stories

Researcher Announced Cure for Hepatitis C

May 22, 2007

The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis, liver cancer and the need for liver transplant, a Virginia Commonwealth University researcher ...

Shorter HCV treatment shows notable success

Jan 02, 2008

[B]It also lowers costs and the risk of serious side effects[/B] Two new randomized controlled trials show that treating Hepatitis C (HCV) with peginterferon and ribavirin for shorter durations can yield success rates sim ...

Recommended for you

Ebola mistakes should serve a lesson says WHO

10 hours ago

The World Health Organization's chief admitted on Sunday that the UN agency had been caught napping on Ebola, saying it should serve as a lesson to avoid similar mistakes in future.

British Ebola nurse discharged from hospital

17 hours ago

A British nurse who contracted Ebola while working as a volunteer in Sierra Leone said she was "happy to be alive" as she was discharged from hospital on Saturday having made a full recovery.

Tide turning in Ebola fight after hard lessons

Jan 24, 2015

A top U.N. official in the fight against Ebola greeted just three patients at one treatment center he visited this week in Sierra Leone. Families in Liberia are no longer required to cremate the remains of ...

Just five Ebola cases left in Liberia: UN

Jan 24, 2015

The United Nations said on Saturday Liberia was dealing with just five remaining cases of Ebola, in the clearest sign yet that the country is nearing the end of the outbreak.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.